AIM1 and LINE-1 Epigenetic Aberrations In Tumor and Serum Relate to Melanoma Progression and Disease Outcome

por Hoshimoto, Sojun, Kuo, Christine, Chong, Kelly, Takeshima, Ling, Takei, Yoshiki, Li, Michelle, Huang, Sharon, Sim, Myung-Shin, Morton, Donald L., Hoon, Dave S.B.
Publicado 2012

B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma

por Wang, Jinhua, Chong, Kelly K., Nakamura, Yoshitaka, Nguyen, Linhda, Huang, Sharon K., Kuo, Christine, Zhang, Wang, Yu, Hua, Morton, Donald L., Hoon, Dave S.B.
Publicado 2013

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

por Leung, Anna M., Lee, Agnes Fermin, Ozao-Choy, Junko, Ramos, Romela Irene, Hamid, Omid, O’Day, Steven J., Shin-Sim, Myung, Morton, Donald L., Faries, Mark B., Sieling, Peter A., Lee, Delphine J.
Publicado 2014

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5(th)–6 (th)2011”

por Ascierto, Paolo A, Grimaldi, Antonio M, Curti, Brendan, Faries, Mark B, Ferrone, Soldano, Flaherty, Keith, Fox, Bernard A, Gajewski, Thomas F, Gershenwald, Jeffrey E, Gogas, Helen, Grossmann, Kenneth, Hauschild, Axel, Hodi, F Stephen, Kefford, Richard, Kirkwood, John M, Leachmann, Sancy, Maio, Michele, Marais, Richard, Palmieri, Giuseppe, Morton, Donald L, Ribas, Antoni, Stroncek, David F, Stewart, Rodney, Wang, Ena, Mozzillo, Nicola, Marincola, Franco M
Publicado 2012